DEA proposes placing five obscure sedatives with names from a chemistry quiz
Published Date: 7/25/2025
Proposed Rule
Summary
The DEA wants to make five substances—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—officially illegal by putting them in Schedule I, the strictest drug category. This means anyone making, selling, or using these drugs will face serious legal consequences. Comments on this plan are open until August 25, 2025, so speak up before then!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Permanent Schedule I listing and sanctions
DEA proposes to permanently add clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam (and their salts and isomers) to Schedule I. If finalized, anyone who manufactures, distributes, imports, exports, researches, conducts instructional activities or chemical analysis with, or possesses these substances would be subject to the CSA's Schedule I regulatory controls and administrative, civil, and criminal sanctions.
Mandatory DEA registration and controls for handlers
If finalized, any person who handles these five substances must be registered with DEA and comply with Schedule I requirements including security rules, labeling and packaging rules, manufacturing quotas, initial and biennial inventories, records and reporting, order-form requirements, and import/export compliance (citing 21 U.S.C. and 21 CFR authorities). The rule explicitly requires an initial inventory on the date a registrant first handles controlled substances and a new inventory every two years.
Very small number of suppliers affected
DEA identified 10 entities supplying these substances (per the SciFinder database), of which 2 have already registered with DEA; DEA expects only 8 additional suppliers would be impacted. DEA estimates affected suppliers would account for about 0.73 percent of small entities in the smallest NAICS industry listed (325412), and therefore concludes the rule would not have a significant economic impact on a substantial number of small entities.
No accepted medical use in United States
DEA (with HHS) states clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam are not approved by FDA and have no currently accepted medical use in treatment in the United States. HHS concluded these substances lack accepted safety for use under medical supervision.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22955, Troy R. Lehman, D.O.; Decision and Order
Troy R. Lehman, D.O., lost his DEA registration because he didn’t have the proper state permission and lied on his renewal forms. Since he didn’t ask for a hearing, the DEA revoked his registration by default, stopping him from handling controlled substances. This change is effective immediately and means he can no longer legally work with these drugs.
2026-23006, Importer of Controlled Substances Application: NSI Lab Solutions LLC
NSI Lab Solutions LLC wants to become an official importer of certain controlled substances, like Amineptine and Mesocarb. People who make or use these drugs can share their thoughts or ask for a hearing by December 14, 2026. This move could affect companies handling these substances and involves a formal review process with no immediate cost changes announced.
Previous / Next Documents
Previous: 2025-14001, Amendment of Class D Airspace and Establishment of Class E2 Airspace Over Hampton Roads, VA
The FAA is updating the airspace rules over Langley Air Force Base in Hampton Roads, VA, because the control tower will now operate part-time. They’re changing the Class D airspace and creating new Class E airspace to keep flights safe and organized. Pilots and local air traffic controllers should note these changes, and comments are open until September 8, 2025, with no extra costs involved.
Next: 2025-14060, Regulatory Publication and Review Under the Economic Growth and Regulatory Paperwork Reduction Act of 1996
The OCC, Federal Reserve, and FDIC are reviewing old banking rules to cut out unnecessary paperwork and make things easier for banks and their holding companies. They’re asking for public comments on the last set of rules by October 23, 2025. This review aims to save time and money while keeping banking safe and fair.